-
Aprotinin Workflows for Protease Research
2026-08-16
Aprotinin enables controlled, reversible inhibition of trypsin, plasmin, and kallikrein in biochemical, inflammation, and fibrinolysis studies. This guide pairs practical BPTI assay design with lessons from an economical GRO-seq workflow, while clearly separating validated applications from exploratory cross-domain ideas.
-
Carrier-Platin and Rapid ROS-Driven Cancer Cell Death
2026-08-15
Liu et al. developed carrier-platin, a platinum-based nanotherapeutic that confines ultrasmall platinum nanoparticles within a poly(amino acid) carrier to generate a rapid intracellular ROS burst. The resulting cancer-cell death occurs within minutes, is independent of DNA damage, and differs from canonical apoptosis and ferroptosis, while showing activity in multidrug-resistant tumor models with limited systemic toxicity.
-
EZ Cap™ Human PTEN mRNA: Assay Design
2026-08-14
EZ Cap™ Human PTEN mRNA (ψUTP) enables controlled PTEN restoration studies with Cap 1, pseudouridine, and a poly(A) tail. This article presents a causal assay-design framework linking mRNA engineering, delivery, PI3K/Akt signaling, and cancer research outcomes.
-
FK866 (APO866): NAMPT Inhibition in Cancer
2026-08-14
FK866, also called APO866, is a potent non-competitive NAMPT inhibitor that lowers intracellular NAD and ATP. It is a research tool for hematologic cancer research, especially acute myeloid leukemia (AML) treatment research, but its activity is model-dependent and does not establish clinical efficacy.
-
ASCH Proteins and N4-Acetylcytidine Processing
2026-08-13
Meng et al. define how the ASCH-domain enzyme EcYqfB converts free N4-acetylcytidine into cytidine while showing that it is not responsible for removing ac4C from RNA. Comparative structures of EcYqfB, mouse EOLA1, and the human TRIP4-ASCH domain clarify substrate-pocket differences and support more precise designs for RNA modification and nucleotide-processing studies.
-
Protease Inhibitor Cocktail for Lipid Droplet Assays
2026-08-13
Preserve DFCP1–ATGL complexes, lipid-droplet proteins, and signaling readouts during starvation experiments with a water-soluble, EDTA-containing inhibitor mixture. This workflow-focused guide explains when to use the cocktail, how to protect samples without compromising downstream assays, and how to troubleshoot metal-sensitive applications.
-
G-Quadruplexes, TDP-43 Condensation, and Toxicity
2026-08-12
Oldani et al. show that G-quadruplexes directly influence TDP-43 aggregation, localization, and toxicity across biochemical and cellular models. The study supports a structure-focused view of RNA–protein misfolding and suggests that manipulating G-quadruplex populations could modulate disease-relevant TDP-43 condensates, while remaining preclinical.
-
Sumatriptan as an Anti-Inflammatory Agent: Review
2026-08-12
This systematic review reframes sumatriptan, traditionally used for migraine and cluster headache, as a potential modulator of inflammatory signaling. By synthesizing 66 studies, it connects 5-HT1B/1D receptor activity with cytokine regulation, nitric oxide signaling, CGRP release, and protection in several experimental injury models.
-
Toremifene Citrate: Reliable Assay Workflows
2026-08-11
A scenario-driven guide to using Toremifene Citrate (SKU B1513) in estrogen receptor signaling, breast cancer research, and cell-based viability workflows. It connects receptor-level potency, solvent handling, concentration design, data interpretation, and vendor-selection criteria to improve experimental consistency.
-
Protease Inhibitor Cocktail for OXPHOS Assays
2026-08-11
Protect intact LRPPRC and OXPHOS-related proteins during cell and tissue extraction with an EDTA-free, broad-spectrum formulation. This workflow connects dependable sample preparation with mechanistic studies of LRPPRC inhibition and dasatinib synergy, while addressing co-IP, Western blot, kinase-assay, and tissue-extract challenges.
-
Topotecan HCl: From DNA Lesions to Translation
2026-08-10
Topotecan HCl offers translational researchers a mechanistically defined topoisomerase 1 inhibitor for linking replication-associated DNA damage with measurable tumor-cell outcomes. This thought-leadership perspective connects target biology, response kinetics, model selection, schedule design, comparative activity, and preclinical safety interpretation.
-
Metformin HCl and AMPK in Vocal Fold Fibrosis
2026-08-09
A translational analysis of how Metformin Hydrochloride engages AMPK-linked antifibrotic biology, what the vocal fold fibrosis evidence supports, and how researchers can design more decision-ready experiments.
-
Nigericin: pH Modulation for Translational Assays
2026-08-08
Nigericin gives researchers a practical way to perturb potassium–proton exchange, intracellular pH, and mitochondrial ion gradients in controlled cell-based assays. This guide translates that mechanism into oncology, mitochondrial, and carefully bounded antibiotic-potentiation workflows while emphasizing controls, solvent handling, and interpretation limits.
-
Nanoparticle mRNA Delivery to Reverse Trastuzumab Resistance
2026-08-07
Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle system for intravenous delivery of PTEN mRNA to trastuzumab-resistant HER2-positive breast cancer models. The approach restored PTEN expression, inhibited persistently active PI3K/Akt signaling, and improved the ability of trastuzumab to suppress tumor growth, while also illustrating the formulation and delivery requirements for systemic in vitro transcribed mRNA therapy.
-
DeferoxamineB: Optimizing Iron Chelation for Cancer Research
2026-08-07
Deferoxamine (DeferoxamineB) stands at the crossroads of iron metabolism and regulated cell death, enabling precision modulation of ferroptosis and cuproptosis pathways in oncology models. This article translates the latest metabolic intervention breakthroughs into robust experimental workflows, actionable troubleshooting, and protocol upgrades that drive reproducible, high-impact results.